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Supplementary Results 
Supplementary Figures 
Supplementary Figure 1. PROTAC parent ligand structures 
 
A) VHL Ligand 
B) ERRα Ligand (Compound 29 in Reference 21) 
C) RIPK2 ligand 
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Supplementary Figure 2: The parent Compound 29 does not degrade ERRα 
3T3-L1 cells were treated for 16 hours with the indicated concentrations of Compound 29, the 
parent ligand for PROTAC_ERRα, followed by harvesting and western blot as described in 
Materials and Methods. Quantification was performed by densitometry, and values are 
normalized to tubulin and the vehicle control. Values are representative of at least two 
experiments.   
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Supplementary Figure 3. Effect of linker on RIPK2 degradation efficiency. 
 
The linker for PROTAC_RIPK2, presented in the main text, was based on a previous generation 
of RIPK2 PROTACs utilizing the tyrosine kinase inhibitor vandetanib. The Structure-Activity 
Relationship for different linkers showed that the three PEG linker afforded maximal degradation. 
Based on these observations, the optimal linker (entry 2) was used in PROTAC_RIPK2.  
 
Targeting Ligand Linker DC50 
Vandetanib 
 
 
Weak 
effect 
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 0.8 µM 
 
No 
effect 
up to 
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 2 µM 
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Supplementary Figure 4. Inhibition of HIF1a peptide binding to VHL complex by 
PROTACs 
 
In a competitive fluorescence polarization experiment, a labeled HIF1α probe was in competition 
with either PROTAC_RIPK2 or PROTAC_RIPK2_epi. The fit sigmoid for PROTAC_RIPK2 
demonstrates an IC50 of 656 nM. Data shown are mean ± SD of at least 4 experiments. 
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 Supplementary Figure 5. Effect of PROTAC_RIPK2 and PROTAC_ERRα on 
ODD-luciferase 
 
 
SH-SY5Y cells expressing luciferase fused to the first Oxygen Dependent Degradation (ODD) of 
HIF1α were treated in triplicate for 16 hours with the indicated compounds. The iron chelator 
Deferoxamine (Sigma) was used as a positive control for hypoxic response. Luciferase levels 
were analyzed in whole cell extracts. ** p<0.0001, *p<0.001, ns: not significant by an ANOVA 
test compare to vehicle. 
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Supplementary Figure 6. Full blots of in cellula protein degradation.  
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Supplementary Figure 7. PROTAC_RIPK2 is not toxic to cells   
(A) Cell viability with RIPK2 PROTACs. THP-1 cells were treated with the indicated 
concentrations of PROTAC_RIPK2 or PROTAC_RIPK2_epi for 16 hours, followed by a 
Trypan Blue assay to determine cell viability. Error bars represent mean and S.D. 
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Supplementary Figure 8. Demonstration of a PROTAC-mediated ternary complex 
between RIPK2 and VHL 
Immunoaffinity enrichment of endogenous VHL from THP-1 cell extract in the presence of RIPK2 
inhibitor, PROTAC_RIPK2 and PROTAC_RIPK2_epi. Immunoblotting demonstrates enrichment 
of VHL (bottom) using an anti-VHL antibody as compared to IgG control.  In the presence of 
various concentrations of PROTAC_RIPK2 but not with PROTAC_RIPK2_epi and RIPK2-binding 
ligand, RIPK2 is selectively co-precipitated (top). Shown are replicate n=1 and replicate n=2. 
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Supplementary Figure 9A.  Kinome specificity of RIPK2 ligand 
The specificity of the RIPK2 ligand was profiled against 371 kinases by KinoBead profiling 
(average of 2 determinations). 
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 Supplementary Figure 9B. Summary of significant activities from kinobead 
profiling of RIPK2-Ligand, PROTAC_RIPK2 and PROTAC_RIPK2_epi 
The PROTACS interact with similar kinases to the parent ligand though absolute pKDapp values 
(mean of n=2) are slightly lower. Both PROTACs show almost identical profiles to each other. 
 
 
  
Protein
pKD	  app
RIPK2-­‐
Ligand	  
PROTAC	  
RIPK2	  
PROTAC	  
RIPK2_epi	  
RIPK2 9.3 8.6 8.5
RIPK3 7.7 6.6 6.7
NLK 6.7 <5.5	   <5.5	  
ABL1/BCR-­‐
ABL 6.5 6.2 6.1
TESK2 6.7 6.1 6.3
TGFBR2 6.2 <5.5	   <5.5	  
MAPKAPK3 6.1 <5.5	   <5.5	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Supplementary Figure 10A. RIPK2 Proteomics time and concentration 
dependence 
Proteomic analysis of protein abundances in response to treatment of THP1 cells with the 
indicated agent at the indicated time. Scatter plots depicting relative abundances of detected 
proteins (circles) from THP-1 cells incubated for 6 h with 30 and 300 nM PROTAC_RIPK2, 30 nM 
Protac_RIPK2_epi and RIPK2-binding ligand compared  to vehicle treated samples. . Proteins 
significantly (p<0.05) regulated in the two biological replicate experiments are indicated in red. 
Relative abundance is plotted replicate 1 vs replicate 2 on a Log2 scale. 
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Supplementary Figure 10B. ERRα Proteomics time and concentration 
dependence 
Proteomic analysis of protein abundances in response to treatment of MCF-7 cells with the 
indicated agent at the indicated time. Scatter plots depicting relative abundances of detected 
proteins (circles) from MCF-7 cells incubated for 4 h with 100 and 500 nM PROTAC_ ERRα and 
ERRα_epi  compared  to vehicle treated samples. Proteins significantly (p<0.05) regulated in the 
two biological replicate experiments are indicated in red. Relative abundance is plotted replicate 
1 vs replicate 2 on a Log2 scale. 
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Tables 
 
Supplementary Table 1: Relative abundance of proteins immunoprecipitated with the 
active or inactive VHL ligands. This data table is graphically represented in Figure 3A. 
See file “Table S1 Bondeson et al”. 
 
Supplementary Table 2: Results summary for ternary complex formation. This data table 
is graphically represented in Figure 3C. See file “Table S4 Bondeson et al” 
 
Supplementary Table 3: Proteomic analysis of RIPK2 phosphorylation sites. LC/MS/MS 
analysis of RIPK2 recombinant protein after incubation in kinase buffer with or without 
ATP. See file “Table S3 Bondeson et al”. 
 
Supplementary Table 4: Results summary for Kinobead competition binding 
experiments. This data table is graphically represented in Supplementary Figure 8. See 
file “Table S2 Bondeson et al”. 
 
Supplementary Table 5: Results summary for expression proteomics. This data table is 
graphically represented in Figure 4 and Supplementary Figure 9. See file “Table S5 
Bondeson et al”. 
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